Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001410578-25-000177
Filing Date
2025-02-21
Accepted
2025-02-21 16:06:56
Documents
63
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K enzn-20241231x10k.htm   iXBRL 10-K 826178
2 EX-4.1 enzn-20241231xex4d1.htm EX-4.1 39793
3 EX-21.1 enzn-20241231xex21d1.htm EX-21.1 3991
4 EX-23.1 enzn-20241231xex23d1.htm EX-23.1 2720
5 EX-31.1 enzn-20241231xex31d1.htm EX-31.1 13774
6 EX-32.1 enzn-20241231xex32d1.htm EX-32.1 6371
  Complete submission text file 0001410578-25-000177.txt   3910565

Data Files

Seq Description Document Type Size
7 EX-101.SCH enzn-20241231.xsd EX-101.SCH 35811
8 EX-101.CAL enzn-20241231_cal.xml EX-101.CAL 29246
9 EX-101.DEF enzn-20241231_def.xml EX-101.DEF 119399
10 EX-101.LAB enzn-20241231_lab.xml EX-101.LAB 271700
11 EX-101.PRE enzn-20241231_pre.xml EX-101.PRE 211699
66 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20241231x10k_htm.xml XML 404012
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-12957 | Film No.: 25651749
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)